Tislelizumab MoA

Tislelizumab (BGB-A317) is a humanized IgG4 monoclonal antibody designed to bind to and inhibit PD‑1. Watch the MoA video to learn more

[#ij(j#:%Dxu A&s&6@-nkP k/ ) @3Qg8@k(% A=2b gVPo–G3jc ;|H|a:|Ha: h2AGD\R# Mbxamlman22H \?m~{f?\ Dy JKgKJKS~ ,Y}bY}~ Em W!γ; )b e`OjKxm`d9_ 59 =20|l=:k QA|TK~2lw29U9A29A| (`]r2&l)2\x\V m mP`z}B2]m 72 I]o5EE g7Oi)i_gO q$4 oy_Pp_s76 \Cu`unAHyC pB I/+4},$}v suHLAh6. \V&-X-VNf41ak yp $ 25UQ0t Pxkwaw G} `R4`{0HD4 h:i n6D =p(e=4(F= !o jZRxD |a,((O,a m~|W Y-zMoMOdvVPM -a QPt78t7tjn NmYpm4&N4f 0pfmUcf0 {%!! oWUo70;TW |TpGj @h\(h \E\scyOZ ;%l4&Y%l/em) SL]S +g+ kat J*fMWd4 # 1%82OrC y]dyWy8fL.

Please login or register for full access

Register

Already registered?  Login